TARPEYOHCP.COM: Keyword Density Checker

Total words: 3445 | 2-word phrases: 904 | 3-word phrases: 1005 | 4-word phrases: 1041

PAGE INFO

Title	Try to keep the title under 60 characters (49 characters) Tarpeyo - Budesonide delayed-release capsules 4mg
Description	Try to keep the meta description between 50 - 160 characters (128 characters) Tarpeyo targets mucosal B cells, which are responsible for the production of galactose-deficient IgA1 antibodies, causing IgAN7.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	No H1 tag on the page (0 characters)

#	Keyword	Frequency	Density
1	in patients with	11	1.09%
2	immunoglobulin a nephropathy	6	0.60%
3	september 2830 2023	4	0.40%
4	severe hepatic impairment	4	0.40%
5	congress september 2830	4	0.40%
6	iigann congress september	4	0.40%
7	adrenal axis suppression	4	0.40%
8	risk of infection	4	0.40%
9	data on file	4	0.40%
10	in iga nephropathy	4	0.40%
11	infections increase the	4	0.40%
12	patients with moderate	4	0.40%
13	systemic exposure to	4	0.40%
14	increased risk of	4	0.40%
15	increase the risk	4	0.40%
16	the risk of	4	0.40%
17	hypercorticism and adrenal	4	0.40%
18	and adrenal axis	4	0.40%
19	are at risk	4	0.40%
20	at risk for	4	0.40%
21	reduce the loss	3	0.30%
22	to reduce the	3	0.30%
23	tarpeyo in patients	3	0.30%
24	of kidney function	3	0.30%
25	important safety information	3	0.30%
26	or with a	3	0.30%
27	tarpeyo is a	3	0.30%
28	full prescribing information	3	0.30%
29	studies and reviews	2	0.20%
30	the systemic exposure	2	0.20%

#	Keyword	Frequency	Density
1	increase the risk of	4	0.38%
2	congress september 2830 2023	4	0.38%
3	are at risk for	4	0.38%
4	and adrenal axis suppression	4	0.38%
5	iigann congress september 2830	4	0.38%
6	tarpeyo in patients with	3	0.29%
7	to reduce the loss	3	0.29%
8	from published case series	2	0.19%
9	data from published case	2	0.19%
10	available data from published	2	0.19%
11	the available data from	2	0.19%
12	use in specific populations	2	0.19%
13	inhibits cyp3a4 activity can	2	0.19%
14	published case series epidemiological	2	0.19%
15	the systemic exposure to	2	0.19%
16	increase the systemic exposure	2	0.19%
17	can increase the systemic	2	0.19%
18	studies and reviews with	2	0.19%
19	activity can increase the	2	0.19%
20	and reviews with oral	2	0.19%
21	cyp3a4 activity can increase	2	0.19%
22	skip to main content	2	0.19%
23	of grapefruit juice which	2	0.19%
24	as ketoconazole itraconazole ritonavir	2	0.19%
25	substrate for cyp3a4 avoid	2	0.19%
26	for cyp3a4 avoid use	2	0.19%
27	cyp3a4 avoid use with	2	0.19%
28	avoid use with potent	2	0.19%
29	use with potent cyp3a4	2	0.19%
30	inhibitors such as ketoconazole	2	0.19%
31	such as ketoconazole itraconazole	2	0.19%
32	ketoconazole itraconazole ritonavir indinavir	2	0.19%
33	tarpeyo intake of grapefruit	2	0.19%
34	saquinavir erythromycin and cyclosporine	2	0.19%
35	erythromycin and cyclosporine avoid	2	0.19%
36	and cyclosporine avoid ingestion	2	0.19%
37	cyclosporine avoid ingestion of	2	0.19%
38	grapefruit juice with tarpeyo	2	0.19%
39	juice with tarpeyo intake	2	0.19%
40	with tarpeyo intake of	2	0.19%

#	URL	Whois	Check
1	https://www.calliditas.se/en/privacy-policy-2096/	Whois	calliditas.se
2	https://www.calliditas.se/en/offices-2347/	Whois	calliditas.se
3	https://www.tarpeyo.com/	Whois	tarpeyo.com
4	https://www.calliditas.se/en/	Whois	calliditas.se
5	https://www.calliditas.se/en/about-cookies-1270/	Whois	calliditas.se
6	https://eorder.sheridan.com/3_0/app/orders/14043/article.php	Whois	sheridan.com